REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Alar Pharmaceuticals Inc. (Taiwan, China)

Main Activities: Pharmaceutical and Medicine Manufacturing
Full name: Alar Pharmaceuticals Inc. Profile Updated: July 08, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Alar Pharmaceuticals Inc., a new drug development company, focusing on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. The company was established in 2016, and headquartered in Taichung City, Taiwan.

Headquarters
5F., No.32, Keya Rd, Daya Dist
Taichung City; Taichung City;

Contact Details: Purchase the Alar Pharmaceuticals Inc. report to view the information.

Website: http://www.alarpharm.com

Basic Information
Total Employees:
Purchase the Alar Pharmaceuticals Inc. report to view the information.
Outstanding Shares:
Purchase the Alar Pharmaceuticals Inc. report to view the information.
Financial Auditors:
Purchase the Alar Pharmaceuticals Inc. report to view the information.
Incorporation Date:
September 23, 2016
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
12.37%
Purchase this report to view the information.
12.08%
Purchase this report to view the information.
3.16%
Purchase this report to view the information.
0.39%
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Alar Pharmaceuticals Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency TWD. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-12.31%▼
EBITDA
-56.55%▼
Net Profit (Loss) for the Period
N/A
Total assets
281.91%▲
Total equity
408.7%▲
Return on Equity (ROE)
N/A
Quick Ratio
36.13%▲
Cash Ratio
7.44%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo